Show simple item record

dc.contributor.authorFan, Xiaoduo
dc.contributor.authorLiu, Emily
dc.contributor.authorFreudenreich, Oliver
dc.contributor.authorCopeland, Paul
dc.contributor.authorHayden, Douglas
dc.contributor.authorGhebremichael, Musie
dc.contributor.authorCohen, Bruce M.
dc.contributor.authorOngur, Dost
dc.contributor.authorGoff, Donald C.
dc.contributor.authorHenderson, David C.
dc.date2022-08-11T08:08:20.000
dc.date.accessioned2022-08-23T15:51:29Z
dc.date.available2022-08-23T15:51:29Z
dc.date.issued2013-04-01
dc.date.submitted2013-07-02
dc.identifier.citationJ Clin Psychopharmacol. 2013 Apr;33(2):226-30. doi: 10.1097/JCP.0b013e31828701d0. <a href="http://dx.doi.org/10.1097/JCP.0b013e31828701d0">Link to article on publisher's site</a>
dc.identifier.issn0271-0749 (Linking)
dc.identifier.doi10.1097/JCP.0b013e31828701d0
dc.identifier.pmid23422397
dc.identifier.urihttp://hdl.handle.net/20.500.14038/28909
dc.description.abstractOBJECTIVE: This study examined the effect of adjunctive intranasal insulin therapy on psychopathology and cognition in patients with schizophrenia. METHODS: Each subject had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of schizophrenia or schizoaffective disorder and been on stable antipsychotics for at least 1 month. In an 8-week randomized, double-blind, placebo-controlled study, subjects received either intranasal insulin (40 IU 4 times per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale and the Scale for Assessment of Negative Symptoms. A neuropsychological battery was used to assess cognitive performance. The assessment for psychopathology and cognition was conducted at baseline, week 4, and week 8. RESULTS: A total of 45 subjects were enrolled in the study (21 in the insulin group and 24 in the placebo group). The mixed model analysis showed that there were no significant differences between the 2 groups at week 8 on various psychopathology and cognitive measures (P > 0.1). CONCLUSIONS: Adjunctive therapy with intranasal insulin did not seem to be beneficial in improving schizophrenia symptoms or cognition in the present study. The implications for future studies were discussed.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23422397&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1097/JCP.0b013e31828701d0
dc.subjectSchizophrenia
dc.subjectInsulin
dc.subjectCognition
dc.subjectPsychopathology
dc.subjectMental and Social Health
dc.subjectMental Disorders
dc.subjectPsychiatry and Psychology
dc.subjectTherapeutics
dc.titleNo effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia
dc.typeJournal Article
dc.source.journaltitleJournal of clinical psychopharmacology
dc.source.volume33
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/114
dc.identifier.contextkey4276330
html.description.abstract<p>OBJECTIVE: This study examined the effect of adjunctive intranasal insulin therapy on psychopathology and cognition in patients with schizophrenia.</p> <p>METHODS: Each subject had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of schizophrenia or schizoaffective disorder and been on stable antipsychotics for at least 1 month. In an 8-week randomized, double-blind, placebo-controlled study, subjects received either intranasal insulin (40 IU 4 times per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale and the Scale for Assessment of Negative Symptoms. A neuropsychological battery was used to assess cognitive performance. The assessment for psychopathology and cognition was conducted at baseline, week 4, and week 8.</p> <p>RESULTS: A total of 45 subjects were enrolled in the study (21 in the insulin group and 24 in the placebo group). The mixed model analysis showed that there were no significant differences between the 2 groups at week 8 on various psychopathology and cognitive measures (P > 0.1).</p> <p>CONCLUSIONS: Adjunctive therapy with intranasal insulin did not seem to be beneficial in improving schizophrenia symptoms or cognition in the present study. The implications for future studies were discussed.</p>
dc.identifier.submissionpathfaculty_pubs/114
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages226-30


This item appears in the following Collection(s)

Show simple item record